Dianomi Therapeutics has licensed a second suite of intellectual property (IP) from the Wisconsin Alumni Research Foundation (WARF) to expand the use of its Mineral Coated Microparticle (MCM) technology into nucleic acid therapy, the company announced recently.

According to a release, the IP includes issued U.S. patents as well as pending U.S. and international patent applications. The biotech company retains exclusive, global rights to pursue nucleic acid therapeutics independently and to build out its commercialization and development programs with other institutions and therapeutic entities.

“Dianomi has demonstrated success in developing and optimizing MCM delivery for biologics and other small molecules,” Dianomi Therapeutics Co-Founder William Murphy said in a statement. “I look forward to Dianomi’s expansion into the area of nucleic acid therapy, building upon the early results of our nucleic acid delivery in regenerative medicine applications.”

As previously reported, Dianomi’s proprietary MCM technology mimics the ability of human bones and teeth to store and protect biologics, potentially leading to lower dosing and enhance patient compliance.